Rusty Konkol wanted to hug everyone he saw during his tour of Iovance Biotherapeutics’ Navy Yard manufacturing facility. The ...

The regenerative medicine market is projected to reach $578 billion by 2033. Cell therapy alone surpassed $8.2 billion this year. And yet the central challenge of the entire sector remains unresolved: ...

The FDA has delayed its target decision date for Orca Bio’s blood cancer cell therapy candidate Orca-T by three months to ...

Johnson & Johnson bets $1B on a Pennsylvania cell therapy plant as earnings momentum, pipeline deals, and MedTech approvals ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

CEO Brian Culley highlighted the progress of OpRegen, noting its differentiation from current anti-complement therapies for dry AMD. He emphasized, “OpRegen has shown evidence of both anatomical and ...

Officials at Caring Cross emphasize that the organization is dedicated to ensuring the global affordability of advanced therapies.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the global launch of the Gibco™ CTS™ ...

Management continues to anticipate the presentation of three-year OpRegen trial data in June 2025, with Culley expressing hope it will “provide additional conviction in our approach.” There remains no ...